MedTrace Logo

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

NCT07104643 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-08-05

No results posted yet for this study

Summary

This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Conditions

Interventions

DRUG

TYK-00540

Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.

DRUG

Enzalutamide

Take orally, 160mg each time, once a day. Take orally with or without meals.

Sponsors & Collaborators

  • TYK Medicines, Inc

    lead INDUSTRY

Principal Investigators

  • Ji Zhu, Doctor of Medicine · Doctor of Medicine

  • Doctor of Medicine · Zhejiang Cancer Hospital, Hangzhou, zhejiang

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104643 on ClinicalTrials.gov